Evidence map›Paper›PMID 40648184›Full record

ArticleSensors (Basel, Switzerland)2025

A Hybrid Compact Convolutional Transformer with Bilateral Filtering for Coffee Berry Disease Classification.

Biniyam Mulugeta Abuhayi, Andras Hajdu

Abstract read
In one paragraph

Article in Sensors (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Biniyam Mulugeta AbuhayiDepartment of Information Technology, University of Gondar, Gondar P.O. Box 196, Ethiopia.ORCID 0000-0003-3717-5499
Andras HajduDepartment of Data Science and Visualization, Faculty of Informatics, University of Debrecen, Egyetem ter 1, 4032 Debrecen, Hungary.ORCID 0000-0003-1718-9770

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Coffee berry disease (CBD), caused by Colletotrichum kahawae, significantly threatens global Coffee arabica production, leading to major yield losses. Traditional detection methods are often subjective and inefficient, particularly in resource-limited settings. While deep learning has advanced plant disease detection, most existing research targets leaf diseases, with limited focus on berry-specific infections like CBD. This study proposes a lightweight and accurate solution using a Compact Convolutional Transformer (CCT) for classifying healthy and CBD-affected coffee berries. The CCT model combines parallel convolutional branches for hierarchical feature extraction with a transformer encoder to capture long-range dependencies, enabling high performance on limited data. A dataset of 1737 coffee berry images was enhanced using bilateral filtering and color segmentation. The CCT model, integrated with a Multilayer Perceptron (MLP) classifier and optimized through early stopping and regularization, achieved a validation accuracy of 97.70% and a sensitivity of 100% for CBD detection. Additionally, CCT-extracted features performed well with traditional classifiers, including Support Vector Machine (SVM) (82.47% accuracy; AUC 0.91) and Decision Tree (82.76% accuracy; AUC 0.86). Compared to pretrained models, the proposed system delivered superior accuracy (97.5%) with only 0.408 million parameters and faster training (2.3 s/epoch), highlighting its potential for real-time, low-resource deployment in sustainable coffee production systems.

Indexed as

CoffeaCoffeeFruitPlant DiseasesAlgorithmsColletotrichumDeep LearningImage Processing, Computer-AssistedSupport Vector MachineCoffeebilateral filteringcoffee berry diseasecompact convolution transformers

Identifiers

PMID40648184
PMCPMC12251858

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.